COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR

Nature Communications

Volumn 7, Issue , 2016, Pages

  Lu, Renquan ^a,b   Hu, Xiaobo ^c   Zhou, Junmei ^d   Sun, Jiajun ^a,b   Zhu, Alan Z ^d   Xu, Xiaofeng ^a,b   Zheng, Hui ^a,b   Gao, Xiang ^a,b   Wang, Xian ^e   Jin, Hongchuan ^e   Zhu, Ping ^d   Guo, Lin ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Gerchi Biotech Research Laboratories   (China)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COP9 SIGNALOSOME; COP9 SIGNALOSOME SUBUNIT 5 PROTEIN; CULLIN; ESTROGEN RECEPTOR ALPHA; GENOMIC DNA; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; MESSENGER RNA; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN PS2; TAMOXIFEN; TAMOXIFEN CITRATE; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; COPS5 PROTEIN, HUMAN; NCOR1 PROTEIN, HUMAN; PEPTIDE HYDROLASE; PROTEASOME; RECEPTOR INTERACTING PROTEIN 140; SIGNAL PEPTIDE; UBIQUITIN;

CANCER; CATALYSIS; DRUG RESISTANCE; ENDOCRINE SYSTEM; GENE EXPRESSION; GENETIC ANALYSIS; INHIBITION; PROTEIN; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UBIQUITINATION; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; MCF-7 CELL LINE; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; COP9 SIGNALOSOME COMPLEX; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; NUCLEAR RECEPTOR CO-REPRESSOR 1; PEPTIDE HYDROLASES; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; TAMOXIFEN; UBIQUITIN;

EID: 84977518373     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12044     Document Type: Article

References (51)

1. Burstein, H. J. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J. Clin. Oncol. 32, 2255-2269 (2014).
2. Charehbili, A. et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat. Rev. 40, 86-92 (2014).
3. Lumachi, F. et al. Endocrine therapy of breast cancer. Curr. Med. Chem. 18, 513-522 (2011).
4. Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011).
5. Normanno, N. et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12, 721-747 (2005).
6. Dees, E. C. & Carey, L. A. Improving endocrine therapy for breast cancer: it's not that simple. J. Clin. Oncol. 31, 171-173 (2013).
7. Arpino, G., Wiechmann, L., Osborne, C. K. & Schiff, R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 29, 217-233 (2008).
8. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009).
9. Renoir, J. M., Bouclier, C., Seguin, A., Marsaud, V. & Sola, B. Antioestrogenmediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells. J. Mol. Endocrinol. 40, 101-112 (2008).
10. Conzen, S. D. Minireview: nuclear receptors and breast cancer. Mol. Endocrinol. 22, 2215-2228 (2008).
11. Naughton, C. et al. Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. Mol. Endocrinol. 21, 2615-2626 (2007).
12. Zhang, Q. X., Borg, A., Wolf, D. M., Oesterreich, S. & Fuqua, S. A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 57, 1244-1249 (1997).
13. Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013).
14. Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451 (2013).
15. Merenbakh-Lamin, K. et al. D538G mutation in estrogen receptor-alpha: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 73, 6856-6864 (2013).
16. Jeselsohn, R. et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 20, 1757-1767 (2014).
17. Clarke, R., Tyson, J. J. & Dixon, J. M. Endocrine resistance in breast cancer - An overview and update. Mol. Cell. Endocrinol. 418(Pt 3): 220-234 (2015).
18. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
19. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013).
20. Cope, G. A. et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298, 608-611 (2002).
21. Peth, A., Berndt, C., Henke, W. & Dubiel, W. Downregulation of COP9 signalosome subunits differentially affects the CSN complex and target protein stability. BMC Biochem. 8, 27 (2007).
22. Cope, G. A. & Deshaies, R. J. COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell 114, 663-671 (2003).
23. Wei, N. & Deng, X. W. The COP9 signalosome. Annu. Rev. Cell Dev. Biol. 19, 261-286 (2003).
24. Callige, M., Kieffer, I. & Richard-Foy, H. CSN5/Jab1 is involved in liganddependent degradation of estrogen receptor {alpha} by the proteasome. Mol. Cell. Biol. 25, 4349-4358 (2005).
25. Lavinsky, R. M. et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl Acad. Sci. USA 95, 2920-2925 (1998).
26. Jepsen, K. et al. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102, 753-763 (2000).
27. Keeton, E. K. & Brown, M. Cell cycle progression stimulated by tamoxifenbound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol. Endocrinol. 19, 1543-1554 (2005).
28. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A. & Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843-852 (2000).
29. Metivier, R. et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115, 751-763 (2003).
30. Garraway, L. A. & Janne, P. A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226 (2012).
31. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
32. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
33. Ciriello, G. et al. The molecular diversity of Luminal A breast tumours. Breast Cancer Res. Treat. 141, 409-420 (2013).
34. Girault, I. et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin. Cancer Res. 9, 1259-1266 (2003).
35. Wolf, D. A., Zhou, C. & Wee, S. The COP9 signalosome: an assembly and maintenance platform for cullin ubiquitin ligases? Nat. Cell Biol. 5, 1029-1033 (2003).
36. Shackleford, T. J. & Claret, F. X. JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div. 5, 26 (2010).
37. Lee, M. H., Zhao, R., Phan, L. & Yeung, S. C. Roles of COP9 signalosome in cancer. Cell Cycle 10, 3057-3066 (2011).
38. Pan, Y., Yang, H. & Claret, F. X. Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. Cancer Biol. Ther. 15, 256-262 (2014).
39. Kouvaraki, M. A. et al. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res. 63, 2977-2981 (2003).
40. Wang, J. et al. Jab1 is a target of EGFR signaling in ERalpha-negative breast cancer. Breast Cancer Res. 10, R51 (2008).
41. Hsu, M. C. et al. Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu. Mod. Pathol. 21, 609-616 (2008).
42. Adler, A. S. et al. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res. 68, 506-515 (2008).
43. Lingaraju, G. M. et al. Crystal structure of the human COP9 signalosome. Nature 512, 161-165 (2014).
44. Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
45. Uhle, S. et al. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J. 22, 1302-1312 (2003).
46. Meerbrey, K. L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl Acad. Sci. USA 108, 3665-3670 (2011).
47. Wiederschain, D. et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8, 498-504 (2009).
48. Ma, Y. et al. Histone deacetylase 3 inhibits new tumour suppressor gene DTWD1 in gastric cancer. Am. J. Cancer Res. 5, 663-673 (2015).
49. Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1, 2315-2319 (2006).
50. Lu, R., Sun, M., Feng, J., Gao, X. & Guo, L. Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer. BMC Cancer 11, 270 (2011).
51. Lu, R. et al. Lactate dehydrogenase 5 expression in Non-Hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis. PLoS ONE 8, e74853 (2013).